Drug Innovation
Commentary
A Bipartisan Regulatory Reform Opportunity: 340B
Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list ...
Blog
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not ...
Commentary
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
Commentary
To help patients save money, Congress needs to tackle the middlemen in health care
As a Republican-controlled House of Representatives with a small majority opens for business in January, one member has especially big ideas for saving patients money on prescription drug costs — and the research to back it up. A year ago, Rep. James Comer (R-KY) released a comprehensive report on the ...
Commentary
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
Commentary
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
Blog
What do Ticketmaster and Pharmacy Benefit Managers have in common?
Popular American singer and songwriter, Taylor Swift, released her newest album ‘Midnights’ in October. The album quickly became the most-streamed album in 24 hours on Spotify, with 184.6 million streams, according to Guinness World Records. Following the release, the artist sought to work with Ticketmaster, a company who arguably has ...
Commentary
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Commentary
Healthcare Competition Isn’t Just A Republican Messaging Point
The midterm elections are tomorrow. Polling suggests Republicans have a shot at winning back both the House and Senate, as voters are coalescing around the GOP’s ideas for reducing inflation and crime. While those ideas might lead to electoral victory, they’re not the only policy priorities on conservatives’ list. Republicans have also promised to ...
Commentary
Human insulin saga: Anomalous, successful 40-year history of the first genetically-modified medicine underscores how regulators can scuttle innovation
October 29th marks the 40th anniversary of one of biotechnology’s most significant milestones — the approval by the FDA of human insulin synthesized in genetically engineered bacteria to treat diabetes.
A Bipartisan Regulatory Reform Opportunity: 340B
Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list ...
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not ...
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
To help patients save money, Congress needs to tackle the middlemen in health care
As a Republican-controlled House of Representatives with a small majority opens for business in January, one member has especially big ideas for saving patients money on prescription drug costs — and the research to back it up. A year ago, Rep. James Comer (R-KY) released a comprehensive report on the ...
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
What do Ticketmaster and Pharmacy Benefit Managers have in common?
Popular American singer and songwriter, Taylor Swift, released her newest album ‘Midnights’ in October. The album quickly became the most-streamed album in 24 hours on Spotify, with 184.6 million streams, according to Guinness World Records. Following the release, the artist sought to work with Ticketmaster, a company who arguably has ...
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Healthcare Competition Isn’t Just A Republican Messaging Point
The midterm elections are tomorrow. Polling suggests Republicans have a shot at winning back both the House and Senate, as voters are coalescing around the GOP’s ideas for reducing inflation and crime. While those ideas might lead to electoral victory, they’re not the only policy priorities on conservatives’ list. Republicans have also promised to ...
Human insulin saga: Anomalous, successful 40-year history of the first genetically-modified medicine underscores how regulators can scuttle innovation
October 29th marks the 40th anniversary of one of biotechnology’s most significant milestones — the approval by the FDA of human insulin synthesized in genetically engineered bacteria to treat diabetes.
